Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 6/20 | 0.65 |
| ▸ | MMP13 | P45452 | 6/20 | 0.65 |
| ▸ | MMP1 | P03956 | 5/20 | 0.65 |
| ▸ | MMP9 | P14780 | 5/20 | 0.65 |
| ▸ | MMP3 | P08254 | 5/20 | 0.65 |
| ▸ | MMP7 | P09237 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | DHFR | P00374 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453607 | 0.94 | ALDH1A1 (0.58) | MMP2MMP13MMP1MMP9MMP3 | |
| Water SCHEMBL10652196 | 0.92 | ALDH1A1 (0.56) | MMP2MMP13MMP1MMP9MMP3 | |
| SCHEMBL13180985 | 0.86 | MMP2 (0.66) | MMP2MMP13MMP1MMP9MMP3 | |
| SCHEMBL11246547 | 0.84 | LMNA (0.53) | MMP2MMP13MMP1MMP9MMP3 | |
| SCHEMBL6613031 | 0.83 | ADAMTS4 (0.70) | MMP2MMP13MMP1MMP9MMP3 | |
| SCHEMBL13515903 | 0.80 | MMP2 (0.59) | MMP2MMP13MMP1MMP9MMP3 | |
| SCHEMBL10785238 | 0.79 | ALDH1A1 (0.54) | MMP2MMP13MMP1MMP9MMP3 | |
| SCHEMBL3618803 | 0.79 | MMP2 (1.00) | MMP2MMP13MMP1MMP9MMP3 | |
| SCHEMBL4431428 | 0.79 | MMP2 (1.00) | MMP2MMP13MMP1MMP9MMP3 | |
| SCHEMBL9231454 | 0.79 | ALDH1A1 (0.51) | ALDH1A1CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180325878-A1 | N-BIARYLAMIDES | BAYER IP GMBH (DE) | 2018-11-15 | — | — | US | disclosed |
| US-9867812-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-01-16 | — | — | US | disclosed |
| US-9867812-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-01-16 | — | — | US | disclosed |
| US-9867812-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-01-16 | — | — | US | disclosed |
| US-20160310474-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2016-10-27 | — | — | US | disclosed |
| US-20160310474-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2016-10-27 | — | — | US | disclosed |
| US-20160310474-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2016-10-27 | — | — | US | disclosed |
| US-9227964-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | disclosed |
| US-9227964-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | disclosed |
| US-9227964-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | disclosed |
| US-7354930-B2 | N-biarylamides | BAYER HEALTHCARE AG (DE) | 2008-04-08 | — | — | US | disclosed |
| US-7354930-B2 | N-biarylamides | BAYER HEALTHCARE AG (DE) | 2008-04-08 | — | — | US | disclosed |
| US-7354930-B2 | N-biarylamides | BAYER HEALTHCARE AG (DE) | 2008-04-08 | — | — | US | disclosed |
| US-20070112023-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-17 | — | — | US | disclosed |
| US-20070112023-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-17 | — | — | US | disclosed |
| US-20070112023-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-17 | — | — | US | disclosed |
| EP-1651645-B1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2007-02-21 | — | — | EP | disclosed |
| EP-1651645-B1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2007-02-21 | — | — | EP | disclosed |
| EP-1651645-A1 | N-BIARYLAMIDES | Bayer HealthCare AG (DE) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005012299-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180325878-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | MMP2 2108/4885MMP13 1871/4885MMP1 4250/4885 |
| US-20070112023-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement | CHRNA7, CHRNA3, CHRNA5 | MMP2 3593/4885MMP13 3866/4885MMP1 3584/4885 |
| US-20160310474-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | MMP2 2108/4885MMP13 1871/4885MMP1 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.